Recent Studies Have Discovered Biomarker Suitability in Pancreatic Cancer Targeting Therapy

A study conducted by researchers from University of Cincinnati has identified biomarker known as phosphatidylserine that could be targeted hence obtaining a therapy to the condition. This study which was published in PLOS ONE also reported that use of a biotherapy that contains Lysosome and phopholipid can also kill pancreatic cancer cells combating the disease. "Only a small number of promising drugs target pancreatic cancer, which is the fourth-leading cause of cancer deaths, with a five-year survival of less than 5 percent," says Xiaoyang Qi, the lead researcher when emphasizing on the importance of adoption of a strategy that would kill the cells. The use of chemotherapy, surgery and radiation has failed to achieve long term solution to pancreatic cancer. Therefore the researchers suggested on the suitability of targeting the potential cause of the condition. "This study provides convincing evidence in support of developing a new therapeutic approach to pancreatic cancer”, when reporting on effectiveness of their findings in cancer management.